PDCD1 and neoplasm: Although this may be advantageous in terms of potentially minimising immune‐related toxicities, it remains to be determined whether intravesical administration of anti‐PD‐1 antibody does indeed cause blockade of PD‐1/PD‐L1 interactions intra‐tumourally and whether this is able to augment a local anti‐tumour immune response in the absence of a systemic immune response.